X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COM701,Nivolumab
Therapeutic Area: Oncology Product Name: COM701
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2021
Details:
The first patient has been dosed in the combination expansion cohort of its ongoing Phase 1 clinical trial evaluating COM701, Compugen's first-in-class anti-PVRIG antibody, in combination with Opdivo® (nivolumab).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
